Breaking News

Evotec Earns Boehringer Milestone

June 23, 2014

Transitions compound into preclinical development

Evotec AG has reached a milestone in its research alliance with Boehringer Ingelheim, triggering a payment of €1.0 million. Evotec transitioned a back-up compound from a respiratory program into preclinical development.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, "We have now achieved twenty three milestones as part of the collaboration with Boehringer Ingelheim. The completed research phase of this alliance has led to significant potential clinical milestones and royalties for compounds that are already in pre-clinical and clinical development if they progress successfully."
 
The companies entered the multi-year, multi-target drug discovery alliance in 2004 to jointly identify and develop candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases.
blog comments powered by Disqus
  • Setting Health-Based Exposure Limits to Support Pharmaceutical Development and Manufacturing

    Setting Health-Based Exposure Limits to Support Pharmaceutical Development and Manufacturing

    B.D. Naumann, P.J. Nigro, U. Bruen, L. Parola, D. Cragin and A. Schatz, Merck & Co., Inc. and Ashland, Inc.||May 5, 2016
    Health-based exposure limits are needed to support risk assessments

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.